Plus   Neg

Aevi Genomic Medicine (GNMX) Has Tumbled To A New Low After Study Failed

Aevi Genomic Medicine (GNMX) announced Monday morning that its SAGA trial of AEVI-001 in adolescents with mGluR mutation positive ADHD did not meet the primary endpoint of reduction on the ADHD rating scale compared to placebo.

Aevi Genomic Medicine gapped open dramatically lower Monday morning and is now down 3.16 at $2.28 on the highest volume of the year. The stock has plunged to a new low for the year.

by RTTNews Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Follow RTT